Literature DB >> 15972645

B7-independent inhibition of T cells by CTLA-4.

Shunsuke Chikuma1, Abul K Abbas, Jeffrey A Bluestone.   

Abstract

CTLA-4 is an inhibitory molecule that regulates T cell expansion and differentiation. CTLA-4 binding to B7-1/B7-2 is believed to be crucial for its inhibitory signal both by competing for CD28 binding to the same ligands and aggregating CTLA-4 to deliver negative signals. In this study, we demonstrate that B7 binding is not essential for CTLA-4 activity. CTLA-4 knockout T cells are hyperresponsive compared with wild-type T cells in B7-free settings. Expression of a B7-nonbinding CTLA-4 mutant inhibited T cell proliferation, cytokine production, and TCR-mediated ERK activation in otherwise CTLA-4-deficient T cells. Finally, transgenic expression of the ligand-nonbinding CTLA-4 mutant delayed the lethal lymphoproliferation observed in CTLA-4-deficient mice. These results suggest that ligand binding is not essential for the CTLA-4 function and supports an essential role for CTLA-4 signaling during T cell activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972645     DOI: 10.4049/jimmunol.175.1.177

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.

Authors:  Je-Min Choi; Seung-Hyung Kim; Jae-Hoon Shin; Thomas Gibson; Byoung-Seok Yoon; Dong-Ho Lee; Seung-Kyou Lee; Alfred L M Bothwell; Jong-Soon Lim; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

2.  Multiscale Modeling of Complex Formation and CD80 Depletion during Immune Synapse Development.

Authors:  István P Sugár; Jayajit Das; Ciriyam Jayaprakash; Stuart C Sealfon
Journal:  Biophys J       Date:  2017-03-14       Impact factor: 4.033

Review 3.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 4.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

5.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

6.  CTLA-4 exon 1 +49A/G polymorphism is associated with renal involvement in pediatric Henoch-Schönlein purpura.

Authors:  Jian-Jun Wang; Yan-Ping Shi; Huang Yue; Wu Chun; Li-Ping Zou
Journal:  Pediatr Nephrol       Date:  2012-06-15       Impact factor: 3.714

7.  The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.

Authors:  Melanie Stumpf; Xuyu Zhou; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

Review 8.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

9.  Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice.

Authors:  Manabu Araki; Denise Chung; Sue Liu; Daniel B Rainbow; Giselle Chamberlain; Valerie Garner; Kara M D Hunter; Lalitha Vijayakrishnan; Laurence B Peterson; Mohamed Oukka; Arlene H Sharpe; Raymond Sobel; Vijay K Kuchroo; Linda S Wicker
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

10.  Molecular basis of cross-species reactivities of human versus porcine CTLA-4.

Authors:  Jaclyn Stromp Peraino; Huiping Zhang; Guoying Li; Christene A Huang; Zhirui Wang
Journal:  Hum Immunol       Date:  2013-04-18       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.